Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing sales7@sinochem-nanjing.com
Follow us:

Raw Material Selection in Synthesis of Pharmaceutical Intermediates

Raw Material Selection in Synthesis of Pharmaceutical Intermediates, identified by its CAS number {cas_number}, is an essential chemical resource widely used in the pharmaceutical sector. This compound features the molecular formula {molecular_formula} and a molecular weight of {molecular_weight}, ensuring precise formulation and traceability in regulated environments. For rigorous chemical identification, it is also known by its IUPAC name {iupac_name} and internationally recognized via its InChIKey {inchikey}, supporting unambiguous tracking across supply chain and regulatory bodies. This raw material is classified as a pharmaceutical intermediate, underlining its critical function as a precursor or reagent in the synthesis of advanced active ingredients and complex molecules.

In terms of physical and chemical properties, the compound presents characteristics aligned with the demands of large-scale pharmaceutical manufacturing. The melting point, if available, provides guidance for solid-state handling, while the density figure allows accurate volumetric calculations and compatibility checks with other solvents or reactants. Flash point and vapor pressure data may inform safe storage and handling, especially for bulk operations or continuous flow synthesis. Whenever available, these physical constants are carefully determined to support robust quality control processes and reproducibility from batch to batch.

From a regulatory and compliance perspective, Raw Material Selection in Synthesis of Pharmaceutical Intermediates meets key international benchmarks. Its registration under the REACH guideline details both the applicable article and the confirmed tonnage band, ensuring legal import and manufacture within the European Economic Area. It is listed or referenced in the TSCA inventory with explicit section citation, indicating its status for commerce in the United States. ICH guidelines specified by their full code and latest revision—along with any relevant impurity or elemental limits—demonstrate the alignment of this material with pharmaceutical quality expectations at a global level. Comprehensive hazard classification in accordance with GHS, including all pertinent H-phrases, signal words, and detailed risks, further supports the safe management of this intermediate. Any references to pharmacopeia chapters enhance confidence in its conformity for regulated drug development, while workplace safety values such as OSHA PEL and NIOSH REL give users concrete boundaries for personnel protection.

This intermediate’s primary value lies in its utility as a raw material for constructing high-purity pharmaceutical intermediates, where stringent synthesis requirements demand chemical consistency and regulatory clarity. It serves as a vital building block in the preparation of target molecules and, consequently, is present in the early or middle stages of drug synthesis pathways. Its role is shaped by both the unique functional groups it provides and the reactivity profile it brings to multistep chemical syntheses. Specific usage in the manufacture of named drugs or active ingredients is often cited in current literature or compound indexes, confirming its integral status in modern pharmaceutical supply chains.

For efficient and safe logistics, the compound is routinely available in bulk industry-standard packaging, such as 25-kilogram drums, 200-kilogram drums, or intermediate bulk containers, supporting both pilot and full-scale process operations. Storage recommendations are based on stability findings—typically from GHS assessments—and advise a cool, dry environment away from direct sunlight or incompatible substances to preserve quality and longevity. The industry-standard shelf life for this class of intermediates is noted, supporting inventory planning and minimizing risk of degradation or loss of performance.

Extensive information on Raw Material Selection in Synthesis of Pharmaceutical Intermediates can be referenced from authoritative sources. For detailed chemical data and regulatory status, see PubChem via https://pubchem.ncbi.nlm.nih.gov/compound/{cid}, the NIST Chemistry WebBook at https://webbook.nist.gov/cgi/cbook.cgi?Name={cas_number}, the ECHA resource at {echa_url}, and the US EPA TSCA Inventory at https://www.epa.gov/tsca-inventory. These platforms ensure that professionals have access to validated specifications, compliance details, and up-to-date industry guidance for informed selection and use.
Related Articles